3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Ovarian Neoplasms
23
Breast Neoplasms
11
Fallopian Tube Neoplasms
10
Multiple Myeloma
7
Carcinoma, Ovarian Epithelial
6
Neoplasms
5
Neoplasms, Plasma Cell
3
Lymphoma
3
Recurrence
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Lymphoma, Non-Hodgkin
2
Carcinoma
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Patient Participation
1
Ovarian Diseases
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Mesothelioma, Malignant
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell
1
Lymphoma, Primary Effusion
1
Liver Neoplasms
1
Interventions
Sorafenib
12
Radiosurgery
5
Gemcitabine
5
Capecitabine
5
Bevacizumab
5
Radiotherapy
4
Fluorouracil
4
Doxorubicin
4
Sunitinib
3
Oxaliplatin
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
seocalcitol
2
regorafenib
2
phosphomannopentaose sulfate
2
atezolizumab
2
Thiotepa
2
Radiofrequency Ablation
2
Melphalan
2
Ifosfamide
2
Granulocyte Colony-Stimulating Factor
2
Fluorodeoxyglucose F18
2
Filgrastim
2
Dexamethasone
2
Cisplatin
2
Chemoembolization, Therapeutic
2
Carboplatin
2
Busulfan
2
Brachytherapy
2
Blood Specimen Collection
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Liver Neoplasms
×
liposomal doxorubicin
×
Clear all
NCT01464593
2022-10-13
ABLATE
Imunon
Phase 2
Terminated
2 enrolled
5 charts